Skinbiotherapeutics Plc Stock Total Debt
| SBTX Stock | 15.88 0.12 0.75% |
SkinBioTherapeutics PLC fundamentals help investors to digest information that contributes to SkinBioTherapeutics' financial success or failures. It also enables traders to predict the movement of SkinBioTherapeutics Stock. The fundamental analysis module provides a way to measure SkinBioTherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SkinBioTherapeutics stock.
SkinBioTherapeutics | Total Debt |
SkinBioTherapeutics PLC Company Total Debt Analysis
SkinBioTherapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current SkinBioTherapeutics Total Debt | 100.65 K |
Most of SkinBioTherapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SkinBioTherapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
SkinBioTherapeutics Net Debt
Net Debt |
|
Based on the latest financial disclosure, SkinBioTherapeutics PLC has a Total Debt of 100.65 K. This is much higher than that of the Personal Care Products sector and significantly higher than that of the Consumer Staples industry. The total debt for all United Kingdom stocks is notably lower than that of the firm.
SkinBioTherapeutics Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SkinBioTherapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SkinBioTherapeutics could also be used in its relative valuation, which is a method of valuing SkinBioTherapeutics by comparing valuation metrics of similar companies.SkinBioTherapeutics is currently under evaluation in total debt category among its peers.
SkinBioTherapeutics Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (13.01) % | ||||
| Current Valuation | 33.81 M | ||||
| Shares Outstanding | 228.44 M | ||||
| Shares Owned By Insiders | 19.32 % | ||||
| Shares Owned By Institutions | 16.45 % | ||||
| Price To Book | 10.01 X | ||||
| Price To Sales | 226.11 X | ||||
| Revenue | 132.06 K | ||||
| Gross Profit | 45.34 K | ||||
| EBITDA | (2.96 M) | ||||
| Net Income | (2.84 M) | ||||
| Total Debt | 100.65 K | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (2.65 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 56.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 36.55 M | ||||
| Total Asset | 2.59 M | ||||
| Retained Earnings | (11.12 M) | ||||
| Working Capital | 1.19 M | ||||
| Net Asset | 2.59 M |
About SkinBioTherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SkinBioTherapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SkinBioTherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SkinBioTherapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SkinBioTherapeutics Stock Analysis
When running SkinBioTherapeutics' price analysis, check to measure SkinBioTherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SkinBioTherapeutics is operating at the current time. Most of SkinBioTherapeutics' value examination focuses on studying past and present price action to predict the probability of SkinBioTherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SkinBioTherapeutics' price. Additionally, you may evaluate how the addition of SkinBioTherapeutics to your portfolios can decrease your overall portfolio volatility.